Federal documents show he disagreed with conclusions the benefits outweighed the risk of side effects, which are rare.

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...